ImmunityBio, Inc. has reported a significant increase in revenue for the second quarter of 2025, with sales reaching $26.4 million, marking a 60% increase from the first quarter of 2025. Year-to-date sales have reached approximately $43 million. Notably, the company has experienced a 246% increase in ANKTIVA unit sales volume in the first half of 2025 compared to the second half of 2024. The net loss attributable to ImmunityBio common stockholders for the six months ended June 30, 2025, was $222.2 million, showing a reduction from the $268.7 million loss during the same period in 2024. This decrease in net loss was primarily attributed to increased product revenue, reduced R&D and SG&A expenses, and lower related-party interest expense. As of June 30, 2025, ImmunityBio's cash position stood at $153.7 million in cash, cash equivalents, and marketable securities. Additionally, the company secured $80 million in equity financing in July 2025, with warrants that could potentially result in additional gross proceeds of up to approximately $96 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.